Hope springs eternal in the face of devastating diseases, and a recent announcement from Gnome Sciences offers a glimmer of it for those battling ALS. Their groundbreaking research suggests a cancer drug could halt the progression of this relentless illness.
On November 11, 2025, Gnome Sciences revealed a significant breakthrough: a study indicating that the cancer drug venetoclax could prevent ALS progression in 100% of treated mice. These mice, who would otherwise succumb to the disease, maintained their mobility, avoided paralysis, and showed significantly less nerve and brain tissue damage. But here's where it gets controversial: The drug also reduced inflammation in the nervous system, a known contributor to ALS's advancement. Considering that there are currently no effective treatments for ALS, a uniformly fatal disease, this is a major step forward.
The research team also delved into the brain tissue of individuals who had passed away from ALS. They discovered that specific proteins, known as BCL2 family proteins, were significantly more active in the neurons affected by ALS compared to healthy ones. These proteins were found in the same areas as other known markers of ALS, implying a key role in the disease's development and potential treatment. These BCL2 proteins are crucial in cellular pathways, including apoptosis, autophagy, mitophagy, and the clearance of misfolded proteins.
"This is a major step forward," stated Dr. Gerard Nuovo, the lead investigator at Gnome Sciences. "We've shown that a drug already approved for cancer can stop ALS before it starts, in animals—and we see the same molecular signatures in human brain tissue. That's incredibly promising. I filed the patent for use of BCL2-targeting drugs like venetoclax to treat ALS and other neurodegenerative conditions to enable a critical path forward."
Dr. A. Mikhail, CEO of Gnome Sciences, added, "We have begun a clinical trial to evaluate the drug in human ALS." He expressed guarded optimism, emphasizing that it is too early to make clinical recommendations, particularly because this class of drugs carries inherent risks. "We are in discussions with several companies to evaluate BCL2 inhibitors in ALS patients."
And this is the part most people miss... The announcement highlights Gnome Sciences' commitment to molecular pathology and translational research. Operating from a CLIA-certified laboratory, they offer advanced scientific services to the pharmaceutical and biotechnology industries. They focus on high-resolution tissue analysis and diagnostic support for preclinical and clinical drug development, accelerating research in ALS, Alzheimer's Disease, cancer, and other diseases.
What do you think? Does this research give you hope? Do you think the potential benefits outweigh the risks of using a drug with known side effects? Share your thoughts in the comments below!
